Amryt Pharma Share Discussion Threads

[papillon] 23/8/2019 20:06

Many thanks alphabravo. Good spot. Excellent news.

Aegerion Creditors Approve Drugmaker’s Chapter 11 Plan
Bankrupt pharmaceutical company’s chapter 11 plan hands control of assets to Amryt Pharma
By Patrick Fitzgerald
Aug. 23, 2019 11:43 am ET

Creditors of Aegerion Pharmaceuticals Inc. have approved a bankruptcy plan that hands the cholesterol drugmaker’s business to Dublin-based Amryt Pharma PLC.
Creditors voted overwhelmingly to support the drugmaker’s chapter 11 plan

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Hopefully we'll see the admissions document soon.

[waterloo01] 23/8/2019 18:05

Excellent and thanks for posting it. Hopefully we'll hear more next week.

[alphabravo321] 23/8/2019 17:45

https://www.wsj.com/articles/aegerion-creditors-approve-drugmakers-chapter-11-plan-11566575038

[alphabravo321] 23/8/2019 12:51

The timeline in the initial announcement did have a health warning advising it was indicative only...The former CEO is objecting to being treated as a creditor as he has legal indemnity from Aegerion, as in they pay his legal bills and they are treating this as a debt owed rather than an obligation

[papillon] 23/8/2019 12:40

What does it say, alphabravo? Only you have to register to read the article.

I'm beginning to doubt that this Aegerion acquisition will happen. The admissions doc was promised for early August and no sign of it. Also no updates from AMYT. Time will tell.

[papillon] 23/8/2019 12:35

The link doesn't load, alphabravo.

[alphabravo321] 23/8/2019 12:20

https://www.law360.com/bankruptcy/articles/1191638/aegerion-pharma-s-ex-ceo-objects-to-ch-11-plan?nl_pk=c1b611ce-45ab-489e-a7e4-cc86bdbee3a4&utm_source=newsletter&utm_medium=email&utm_campaign=bankruptcy

[delta0091] 22/8/2019 17:50

Amryt Pharma: The AIM drug developer potentially sitting on a US$100mln piece of paper

Amryt has a chance of being awarded a priority review voucher, which sell for several times more than the company’s current market cap

[papillon] 22/8/2019 13:14

alphabravo321
5 Aug '19 - 16:48 - 4699 of 4712
0 0 0
Readmission doc due to be published in early Aug, readmission to trading planned for “early Q4”

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Where's this admissions doc, alphabravo? It's late August now and no sign of that bloody admissions doc. I can see the relisting date slipping into 2020.

[papillon] 22/8/2019 13:12

They do indeed, waterloo01.

[waterloo01] 22/8/2019 09:18

See Astra zenica bought a priority review voucher for $95m (down from some years ago). Don't AMYT have one of these if ap101 gets approval?

[delta0091] 20/8/2019 19:16

hxxps://risemedia.net/2019/08/07/acromegaly-drug-market-top-competitors-are-silence-therapeutic-strongbridge-biopharma-plc-amryt-pharma-plc-foresee-pharmaceuticals-co-ltd-ipsen-pharma-and-others/

Acromegaly Drug Market Top Competitors are Silence Therapeutic, Strongbridge Biopharma plc, Amryt Pharma plc, Foresee Pharmaceuticals Co., Ltd, Ipsen Pharma and Others

Acromegaly is a rare hormonal disorder also known as gigantism. It occurs when pituitary gland releases excessive growth hormone in the body due to the tumor formation in the pituitary gland. This abnormal production of growth hormone results in the bone enlargement. It mainly affects the geriatric population.

Global Acromegaly Drug Market is rising gradually with a substantial CAGR of 5.10% in the forecast period of 2019-2026. This rise in market value can be attributed in increase in awareness and concerns regarding the health of patients, increasing prevalence of growth hormone disorders and high expenditure in healthcare sector.

[papillon] 19/8/2019 13:09

Well no new update from AMYT since the result of the AGM RNS dated 10th July. Will this drag into 2020 before AMYT relists? From my previous experience of AIM listed companies (including AMYT) they almost always never stick to the initial timetables.

[chica1] 12/8/2019 15:49

Yes Bermuda I heard of Amryt through Debra Ireland a few years ago.
An excellent charity.

[bermudashorts] 10/8/2019 18:03

DEBRA of America is a high profile Epidermolysis Bullosa medical research charity and they will be hosting their annual benefit evening in New York in October. Amryt is one of three companies (& the only non US one) being recognised with a Partners in Progress award to be presented on the night. Good stuff and well done Amryt.

[diamondstar1] 10/8/2019 10:42

Hi Chica1....As per Newton’s Third Law - Every action has an equal and opposite reaction. Put simply, I have been on this site long enough to realise that Papillon is usually reacting to others comments, rather than irritating others as his primary objective.

As for yourself, all the best with the medical condition which afflicts your family. EB is a nasty disease. Previous trials with episalvan have shown a 10% improvement in the skin healing; I would doubt that you would be able to notice significant improvement in a single participant study!

[chica1] 09/8/2019 17:57

Yes Papillon everyone is anonymous here.I see from you recent posting that you seem to irritate people on every forum you partake in.

Quite sad actually that these boards seem to be your only life!

[papillon] 06/8/2019 22:09

mdalos1
6 Aug '19 - 19:41 - 4702 of 4702
0 0 0
LOLs... absolutely clueless !!

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Don't keep beating yourself up, MADLOSS! PMSL ROFLMAO

[papillon] 05/8/2019 19:44

As soon as the admission document was published FAST returned from suspension on the 31st March 2016



The acquisition of AMYT (an RTO) didn't become effective until 18th April 2016 when the company named changed to Amryt Pharma.



Hence it's possible that AMYT could relist as soon the admission document is published in "early August" and before the Aegerion deal is finalised. Will it? No idea.

[waterloo01] 05/8/2019 17:03

Thanks. Going to be interesting. Not a bad thing being suspended anyhow given the markets.

[alphabravo321] 05/8/2019 16:48

Readmission doc due to be published in early Aug, readmission to trading planned for "early Q4"